Literature DB >> 34818250

Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort.

Vito Fiore1, Andrea De Vito1, Chiara Fanelli1, Nicholas Geremia1, Elija Princic1, Alessandra Nivoli2, Ivana Maida1, Liliana Lorettu1, Giordano Madeddu1,2,3, Sergio Babudieri1.   

Abstract

OBJECTIVE: We aimed to investigate the presence and severity of depressive symptoms among coronavirus disease 2019 (COVID-19) inpatients and any possible changes after their discharge. SUBJECT AND METHODS: We collected data of patients admitted to the Infectious Disease Unit in Sassari, Italy, for COVID-19, from March 8 to May 8, 2020. The Beck Depression Inventory-II (BDI-II) was performed 1 week after admission (T0) and 1 week after discharge (T1). The cutoff point chosen to define the clinical significance of depressive symptoms was 20 (at least moderate).
RESULTS: Forty-eight subjects were included. Mean age was 64.3 ± 17.6 years, and 32 (66.7%) were male. Most frequent comorbidities were cardiovascular diseases (19; 39.6%) and hypertension (17; 35.4%). When performing BDI-II at T0, 21 (43.7%) patients reported depressive symptoms at T0, according to the chosen cutoff point (BDI-II = 20). Eight (16.7%) patients had minimal symptoms. Mild mood disturbance and moderate and severe depressive symptoms were found in 24 (50%), 14 (29.2%), and 2 (4.2%) patients, respectively, at T0. The comparison of the BDI-II questionnaire at T0 with T1 showed a significant improvement in the total score (p < 0.0001), as well as in 4 out of the 5 selected questions of interest (p < 0.05). Univariate analysis showed that kidney failure and the death of a roommate were significantly associated with severity of mood disorders.
CONCLUSION: Mood disturbances and depressive symptoms commonly occur among COVID-19 inpatients. Our results show that COVID-19 inpatients might be at higher risk for developing depressive reactive disorders and could benefit from an early psychological evaluation and strategies improving sleep quality.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Coronavirus disease 2019; Depression; Mental health; Mood disorders; SARS-CoV-2

Mesh:

Year:  2021        PMID: 34818250      PMCID: PMC8739625          DOI: 10.1159/000518490

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  24 in total

1.  Relations of SARS-related stressors and coping to Chinese college students' psychological adjustment during the 2003 Beijing SARS epidemic.

Authors:  Alexandra Main; Qing Zhou; Yue Ma; Linda J Luecken; Xin Liu
Journal:  J Couns Psychol       Date:  2011-07

2.  Patient isolation precautions and 30-day risk of readmission or death after hospital discharge: a prospective cohort study.

Authors:  Darren Lau; Sumit R Majumdar; Finlay A McAlister
Journal:  Int J Infect Dis       Date:  2016-01-02       Impact factor: 3.623

Review 3.  Pandemic palliative care: beyond ventilators and saving lives.

Authors:  Amit Arya; Sandy Buchman; Bruno Gagnon; James Downar
Journal:  CMAJ       Date:  2020-03-31       Impact factor: 8.262

4.  Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience.

Authors:  A De Vito; N Geremia; E Princic; C Fanelli; C M Panu Napodano; A A Muredda; V Fiore; I Maida; A G Fois; S Babudieri; G Madeddu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2021-01       Impact factor: 3.507

5.  Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?

Authors:  R N Dallocchio; A Dessì; A De Vito; G Delogu; P A Serra; G Madeddu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2021-03       Impact factor: 3.507

6.  Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis.

Authors:  S Di Legge; M C Piattella; C Pozzilli; P Pantano; F Caramia; I F Pestalozza; A Paolillo; G L Lenzi
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

7.  "Death is a better option than being treated like this": a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients.

Authors:  R Huque; H Elsey; F Fieroze; J P Hicks; S Huque; P Bhawmik; I Walker; J Newell
Journal:  BMC Public Health       Date:  2020-06-03       Impact factor: 3.295

8.  Care/punishment dilemma in COVID-19 hospital treatment.

Authors:  Anna Varfolomeeva
Journal:  Soc Anthropol       Date:  2020-06-11

9.  Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors.

Authors:  Mario Gennaro Mazza; Rebecca De Lorenzo; Caterina Conte; Sara Poletti; Benedetta Vai; Irene Bollettini; Elisa Maria Teresa Melloni; Roberto Furlan; Fabio Ciceri; Patrizia Rovere-Querini; Francesco Benedetti
Journal:  Brain Behav Immun       Date:  2020-07-30       Impact factor: 7.217

10.  Anxiety and Suicidality in a Hospitalized Patient with COVID-19 Infection.

Authors:  Danny Epstein; Wisam Andrawis; Ari M Lipsky; Hiba Abu Ziad; Moshe Matan
Journal:  Eur J Case Rep Intern Med       Date:  2020-04-09
View more
  2 in total

1.  Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study.

Authors:  Vito Fiore; Andrea De Vito; Paola Bagella; Elija Princic; Anna Antonella Mariani; Lucia Denti; Alessandro Giuseppe Fois; Giordano Madeddu; Sergio Babudieri; Ivana Maida
Journal:  Healthcare (Basel)       Date:  2022-05-22

2.  Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature.

Authors:  Vito Fiore; Rosalba Beretta; Andrea De Vito; Aleksandra Barac; Ivana Maida; David David Joeseph Kelvin; Claudia Piu; Vincenzo Lai; Giordano Madeddu; Salvatore Rubino; Goran Stevanovic; Stefan Korica; Sergio Babudieri
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.